ReviewJournal of the Egyptian National Cancer Institute2026
Nanomedicine against oxaliplatin-induced peripheral neuropathy: hypotheses and research perspectives on ion channels and immune microenvironment.
Review in Journal of the Egyptian National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxaliplatin serves as a cornerstone chemotherapeutic agent for solid tumors (e.g., colorectal and gastric cancers); however, its associated dose-limiting peripheral neuropathy (OIPN) severely compromises patients’ quality of life and treatment completion rates. OIPN manifests as acute cold-induced paresthesia and chronic cumulative sensory neuropathy, with complex, incompletely elucidated pathophysiological mechanisms. This review systematically summarizes the core molecular mechanisms of OIPN, focusing on: (1) sensitization of transient receptor potential vanilloid/ankyrin channels (TRPV1/TRPA1), (2) dysregulated expression and function of voltage-gated sodium channels (NaV1.7, NaV1.8), and (3) the critical role of p38 mitogen-activated protein kinase (p38-MAPK) pathway activation in neuronal hyperexcitability and pain signal transduction within dorsal root ganglion (DRG) sensory neurons. Additionally, we delve into dynamic alterations of the DRG immune microenvironment (notably macrophages and T cells) during OIPN initiation/progression, as well as their crosstalk with neurons. To address the clinical dilemma of limited effective preventive/therapeutic approaches, this review outlines limitations of current strategies and highlights the advantages of nanotechnology-based drug delivery systems in enhancing neuroprotective agent bioavailability and enabling targeted delivery. Finally, we hypothesize the integration of salidroside (a natural product with anti-inflammatory/antioxidant properties) with nanotechnology, and propose leveraging cutting-edge tools (spatial transcriptomics, single-cell RNA sequencing) to elucidate its potential mechanistic action in OIPN—providing a theoretical hypothesis and exploratory research directions for precision OIPN prevention and treatment, in the absence of any empirical evidence for salidroside’s efficacy in this specific pathological context.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.